Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03583528 : DOTATOC PET/CT for Imaging NET Patients
AgesMin: 18 Years Max: 100 Years
Inclusion Criteria:

All subjects:

- World health organization performance status 0-2

- Able to provide written informed consent/assent (or consent by guardian for subjects
<19 years)

- Patients must be able to tolerate the physical/logistical requirements of completing a
PET scan including lying flat for up to 30 minutes and tolerating intravenous
cannulation for injection.

Patients must require imaging for either staging or re-staging of:

- Gastroenteropancreatic tumors (e.g. carcinoids, gastrinoma, insulinoma, glucagonoma,
VIPoma, etc.), functioning and non-functioning

- Sympathoadrenal system tumors (phaeochromocytoma, paraganglioma, neuroblastoma,

- Medullary thyroid carcinoma

- Pituitary adenoma

- Medulloblastoma

- Merkel cell carcinoma

- Small-cell lung cancer (mainly primary tumors)

- Meningioma

- Or any other NET / with potential for overexpression of SSTR

Exclusion Criteria:

- Pregnancy

- Patients who are medically unstable ex: acute cardiac or respiratory distress,

- Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot
fit through the PET/CT bore (diameter 70cm).
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557